4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% Higher - Here's Why

Key Points

• Shares jumped about 8.7% to $9.98 after 4D reported a surprise quarterly beat — EPS $0.43 vs. -$0.53 expected and revenue of $85.09M versus $30.86M consensus — even though the company remains unprofitable with a negative net margin and ROE.
• Sell-side sentiment is largely bullish with seven Buy ratings, a consensus target of $32.71, and recent price targets from analysts ranging roughly $26–$36 following upgrades and new coverage.
• 4D is a clinical-stage gene therapy company (GEA AAV platform) with a market cap near $508M, a negative P/E, and very high institutional ownership at 99.27%.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) traded up 8.7% during trading on Wednesday . The stock traded as high as $9.98 and last traded at $9.98. 333,548 shares were traded during mid-day trading, a decline of 55% from the average session volume of 741,537 shares. The stock had previously closed at $9.18.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on FDMT. Chardan Capital reaffirmed a "buy" rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Royal Bank Of Canada increased their target price on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an "outperform" rating in a report on Thursday, March 19th. Barclays initiated coverage on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 28th. They issued an "overweight" rating and a $33.00 target price for the company. HC Wainwright reiterated a "buy" rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 21st. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $32.71.

4D Molecular Therapeutics Trading Up 8.4%

The company has a market cap of $507.95 million, a P/E ratio of -4.10 and a beta of 2.99. The business has a 50 day moving average price of $8.82 and a 200-day moving average price of $9.17.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.96. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 31.75%. The business had revenue of $85.09 million during the quarter, compared to analysts' expectations of $30.86 million. On average, sell-side analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several hedge funds have recently bought and sold shares of FDMT. BVF Inc. IL boosted its stake in shares of 4D Molecular Therapeutics by 1.5% during the 2nd quarter. BVF Inc. IL now owns 4,629,289 shares of the company's stock worth $17,175,000 after acquiring an additional 68,000 shares during the period. XTX Topco Ltd bought a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at $292,000. Quadrature Capital Ltd bought a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at $42,000. Dynamic Technology Lab Private Ltd lifted its holdings in 4D Molecular Therapeutics by 35.6% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 16,369 shares of the company's stock valued at $61,000 after purchasing an additional 4,295 shares during the last quarter. Finally, Peapod Lane Capital LLC boosted its position in 4D Molecular Therapeutics by 1.1% during the third quarter. Peapod Lane Capital LLC now owns 322,081 shares of the company's stock worth $2,799,000 after purchasing an additional 3,544 shares during the period. 99.27% of the stock is currently owned by institutional investors and hedge funds.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.